Michael Rosenblatt

Michael A. Rosenblatt was the founder of Theracrine, Inc. (2006) and Radius Health, Inc. (2003) with the title of Director.
Current jobs include Director at Ferring Pharmaceuticals, Inc. (2016), Non-Executive Director at Perspectum Ltd., Director at Cygnal Therapeutics, Inc. (2016), Director at Perspectum Group Ltd. (2022), Senior Advisor at Flagship Pioneering, Inc. (2022), and Advisor at PureTech Health LLC.
Former jobs include Non-Executive Director at Shire Plc (2008), Non-Executive Director at Shire Plc (2008-2009), Director at ProScript, Inc., Director at Project HOPE-The-People-To-People Health Foundation, Inc., Director at Harvard Mit Health Sciences & Technology (1998), Independent Director at Axcella Health, Inc. (2022-2023), Independent Director at Rubius Therapeutics, Inc. (2014-2023), Non-Executive Director at PYC Therapeutics Ltd. (2021-2025), Director at Ohana Biosciences, Inc., Director at Cobalt Biomedicine, Inc., Independent Director at Azenta, Inc. (2018-2025), Chief Medical Officer & Executive Vice President at Merck & Co., Inc. (1984-2016), Chief Medical Officer at Schering-Plough Corp., Principal at The General Hospital Corp.
(1981-1984), Senior Vice President-Academic Programs at CareGroup, Inc. (2000), President at Beth Israel Deaconess Medical Center, Inc. (1996-2003), Member-Scientific Counselors Board at National Institute of Diabetes & Digestive & Kidney Diseases, Senior Vice President-Research at Merck Research Laboratories Massachusetts LLC, Professor at Harvard Medical School, Senior Vice President-Research at Merck Sharp & Dohme Corp.
(1992), Professor at Molecular Medicine LLC, and Dean at Tufts University School of Medicine.
Education includes an undergraduate degree from The Trustees of Columbia University in The City of New York and a doctorate from Harvard Medical School.